Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages
Haemonetics Corporation (NYSE:HAE) has received a "Moderate Buy" consensus rating from eleven analysts, with an average 12-month price target of $84.44. The company recently surpassed Q earnings estimates with $1.31 EPS and $338.97 million in revenue, also issuing strong FY2026 guidance. Institutional investors have been actively adjusting their stakes, indicating continued interest and confidence in the medical instruments supplier.
Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc.
Heartland Advisors Inc. significantly reduced its stake in Haemonetics Corporation (NYSE:HAE) by 38.6% in the third quarter, now owning 96,125 shares valued at approximately $4.69 million. Despite this, Haemonetics reported strong Q3 earnings, beating analyst expectations with $1.31 EPS and $338.97 million in revenue, and institutional investors collectively hold about 99.67% of the company's stock. The company maintains a consensus "Moderate Buy" rating with an average price target of $84.44.
ABN Amro Investment Solutions Buys Shares of 200,000 Haemonetics Corporation $HAE
ABN Amro Investment Solutions has acquired a new 200,000-share position in Haemonetics Corporation, valued at approximately $186,000. Other institutional investors like Norges Bank, SG Capital, and River Road also increased their stakes, leading to institutional ownership of about 99.67% of the stock. Haemonetics recently beat EPS estimates and provided FY2026 guidance, with analysts holding a "Moderate Buy" consensus rating.
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
Baird has lowered its price target for Haemonetics Corporation (HAE) to $81 from $99 while maintaining an Outperform rating, following the company's Q3 results and revised segment estimates. Despite the lowered target, Baird sees upside potential in the Plasma business. In contrast, Barrington Research increased its price target to $94 from $93, based on solid guidance for fiscal year 2026, offering a more positive outlook for the company's near-term future.
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
Baird has updated its model for Haemonetics Corporation (HAE) following the company's Q3 results, lowering its price target to $81 from $99 while maintaining an Outperform rating. This revision accounts for updated estimates in certain segments, though Baird sees upside potential in the Plasma business. In contrast, Barrington Research raised its price target for HAE to $94 from $93, citing solid guidance for fiscal year 2026 despite a mixed quarterly performance.
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 21.7%
Short interest in Haemonetics Corporation (NYSE:HAE) decreased by 21.7% in January, totaling 2,411,300 shares, which represents about 5.3% of shares sold short with a days-to-cover ratio of 2.6 days. The company recently exceeded quarterly earnings estimates with $1.31 EPS and $338.97M in revenue, providing FY2026 guidance between $4.90 and $5.00 EPS. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $84.44.
Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc.
Principal Financial Group Inc. reduced its stake in Haemonetics Corporation (NYSE:HAE) by 11.6% in the third quarter of 2025, selling 19,413 shares. Despite this sale, institutional investors and hedge funds still own 99.67% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for HAE, with an average target price of $84.44.
Haemonetics Releases 2024-2025 Corporate Responsibility Report
Haemonetics (HAE) has released its 2024-2025 Corporate Responsibility Report, making it available on its website. The report is furnished, not filed, under U.S. securities laws, indicating an effort to share ESG information while limiting legal exposure. TipRanks' AI Analyst, Spark, rates HAE as Neutral due to weak technicals but notes reasonable valuation and raised EPS/FCF guidance.
Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell?
Haemonetics Corporation (HAE) reported lower third-quarter fiscal 2026 sales but higher net income, alongside guidance for first-quarter and full-year 2026 revenue. The company is experiencing weakness in its Interventional Technologies segment, which is being offset by strong performance in plasma and blood management. Haemonetics also completed a US$75 million share repurchase program, highlighting management's efforts to return cash to shareholders while navigating sector challenges.
5 Revealing Analyst Questions From Haemonetics's Q4 Earnings Call
Haemonetics's Q4 results exceeded revenue and earnings expectations, though the market reacted negatively due to caution. While plasma growth was strong, challenges in Interventional Technologies led to revenue decline. Analyst questions focused on the sustainability of plasma gains, recovery in Interventional Technologies, the impact of the VIVUSHORE acquisition, plasma market cycles, and growth opportunities in ambulatory surgery centers.
Skylands Capital LLC Has $3.97 Million Stock Holdings in Haemonetics Corporation $HAE
Skylands Capital LLC significantly increased its stake in Haemonetics Corporation (NYSE:HAE) by 195.4% in the third quarter, bringing its total holdings to 81,369 shares valued at approximately $3.97 million. This move comes as Haemonetics has reported strong financial performance, beating recent earnings estimates with EPS of $1.31 and revenue of $338.97 million, and providing optimistic FY2026 guidance. Despite some mixed views from analysts regarding price targets, the stock maintains a "Moderate Buy" consensus rating with an average price target of $84.44.
How Haemonetics Corporation (HAE) Affects Rotational Strategy Timing
This article analyzes Haemonetics Corporation (HAE) and its impact on rotational strategy timing, noting weak near and mid-term sentiment but a neutral long-term outlook. It highlights unique trading strategies developed by AI models, including position, momentum breakout, and risk hedging, to optimize gains and manage risk. The report also provides multi-timeframe signal analysis with support and resistance levels for various holding periods.
Key Players in the Autotransfusion Systems Market - Haemonetics Corporation, Fresenius Kabi, LivaNova, Medtronic, Terumo Corporation
This article examines the key players in the autotransfusion systems market, highlighting their competitive strategies, strengths, weaknesses, and investment opportunities. Companies like Haemonetics, Fresenius Kabi, LivaNova, Medtronic, Becton, Dickinson and Company (BD), Brightwake, and Terumo Corporation are discussed based on their innovation, market positioning, and regional expansion efforts. The article also provides a SWOT analysis of the market and outlines recent developments and key investment themes.
Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
Haemonetics increased its fiscal year 2026 guidance, projecting 8-10% organic revenue growth, up from the previous 6-8% forecast. This optimistic outlook is fueled by strong performance in its plasma and blood management businesses. The company anticipates non-GAAP earnings per share to grow by 10-13%.
Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
Haemonetics has raised its fiscal 2026 guidance, projecting 8%-10% organic revenue growth. This optimistic outlook is primarily driven by strong performance in its plasma and blood management segments, indicating continued market expansion and operational success for the company.
Haemonetics (HAE) Margin Strength In Q3 2026 Reinforces Earnings Led Bullish Narratives
Haemonetics (HAE) reported strong Q3 2026 results with US$339 million in revenue and US$0.96 basic EPS, demonstrating improved net profit margins of 13.3% compared to 9.5% last year. While revenue growth forecasts are modest at 5.5% annually, the company's 35% year-over-year earnings growth and higher margins support a bullish narrative focused on profit quality. Despite a mixed valuation story and high debt levels flagged by critics, the stock trades at a lower P/E than peers, with analyst targets significantly above its current price.
Haemonetics Corporation Q3 Fiscal 2026 Results
Haemonetics Corporation (HAE) announced its Q3 fiscal 2026 financial results, reporting a revenue of $339 million, a 2.7% decrease, but an adjusted EPS increase of 10.1% to $1.31. The company raised its fiscal 2026 guidance for adjusted EPS to $4.90-$5.00 and free cash flow to $200-$220 million, driven by strong performance in Blood Management Technologies and Plasma. CEO Chris Simon highlighted margin expansion and cash flow reflecting the strength of core businesses.
Haemonetics Q3 Earnings Call Highlights
Haemonetics reported strong Q3 earnings with $339 million in revenue and raised its full-year guidance for both revenue and free cash flow, driven by significant organic growth in plasma and Blood Management Technologies. Despite a decline in Interventional Technologies due to esophageal-cooling weakness, the company saw expanded margins and robust cash generation, along with strategic acquisitions and share repurchases. Management is optimistic about continued growth, particularly in its plasma platform and TEG hospital blood management franchise.
Citigroup Lowers Price Target for Haemonetics (HAE) to $75 | HAE Stock News
Citigroup has lowered its price target for Haemonetics (HAE) to $75 from $88, while maintaining a Neutral rating on the stock. This adjustment comes despite other analysts, like Barrington Research and BTIG, having more optimistic ratings and price targets in the recent past. Haemonetics, a medical products company focused on blood and plasma solutions, has an average target price of $90.70 from 10 analysts, suggesting a significant upside from its current price.
Haemonetics Corporation (NYSE:HAE) Q3 2026 Earnings Call Transcript
Haemonetics Corporation reported its Q3 2026 earnings, posting revenue of $339 million and a miss on EPS expectations at $0.952 against an anticipated $1.27. Despite portfolio transitions, the company saw strong organic growth in plasma and blood management technologies, driven by innovation and share gains, leading to updated full-year guidance for revenue, earnings, and free cash flow. The interventional technologies segment faced declines, but management expressed confidence in its return to growth in FY 2027 with new product launches and strategic actions.
HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results
Haemonetics (HAE) reported better-than-expected Q4 CY2025 revenue and adjusted EPS, driven by strong plasma business momentum, though overall revenue declined by 2.7% year-on-year due to weakness in hospital-based Interventional Technologies. Management provided optimistic full-year Adjusted EPS guidance and aims for recovery in Interventional Technologies through new product launches and commercial efforts, while acknowledging that future operating margin gains will moderate. The company remains focused on organic growth, debt reduction, and strategic acquisitions, leveraging strong cash flow.
Haemonetics stock maintains Market Outperform rating at Citizens on strong plasma growth
Haemonetics (NYSE:HAE) received a maintained Market Outperform rating and $100.00 price target from Citizens after its fiscal third-quarter 2026 results surpassed expectations. The medical technology company showed strong performance in its Plasma and Blood Center segments, contributing to a 2% top-line and 5% bottom-line beat, and raised its free cash flow guidance. Despite a recent stock decline, management's aggressive share repurchases and positive earnings led to Bairds price adjustment while still maintaining an Outperform rating.
Haemonetics tops Q3 forecasts and raises fiscal 2026 outlook
The article reports that Haemonetics exceeded its Q3 forecasts and subsequently raised its fiscal year 2026 outlook. This positive financial performance indicates strong operational results for the company.
Haemonetics: Fiscal Third Quarter Earnings Overview
Haemonetics Corp. announced strong fiscal third-quarter results, reporting a net profit of $44.7 million, or $0.95 per share. Adjusted earnings reached $1.31 per share, surpassing analyst predictions of $1.27 per share. The company also exceeded revenue forecasts, generating $339 million, and projects full-year earnings between $4.90 and $5.00 per share.
Haemonetics's (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars
Haemonetics (NYSE:HAE) exceeded Wall Street's revenue expectations in Q4 CY2025 with $339 million, despite a 2.7% year-on-year sales decline. The company's adjusted EPS of $1.31 also beat consensus estimates by 4.8%, leading to an 8.7% stock increase post-results. Management raised its full-year Adjusted EPS guidance to $4.95 at the midpoint.
Haemonetics: Fiscal Third Quarter Earnings Overview
Haemonetics Corp. reported strong fiscal third-quarter results, with a net profit of $44.7 million and adjusted earnings of $1.31 per share, surpassing analyst expectations. The company also exceeded revenue forecasts, generating $339 million, and projects full-year earnings between $4.90 and $5.00 per share. This positive performance was highlighted by Zacks Investment Research.
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that its third-quarter fiscal year 2026 financial results, which ended on December 27, 2025, are now available on the company's Investor Relations website. The company will also host a conference call and webcast on February 5, 2026, at 8:00 a.m. ET to discuss these results. Supplemental materials, including the earnings release and presentation, have also been posted online.
HAEMONETICS CORP SEC 10-Q Report
Haemonetics Corp (HAE) released its Form 10-Q report for Q3 fiscal year 2025, detailing financial results and business operations. The report showed increased gross profit, operating income, and net income, despite a slight decrease in net revenues. Key business highlights include strategic acquisitions in the interventional cardiology market and continued global expansion.
What To Expect From Haemonetics's (HAE) Q4 Earnings
Haemonetics (HAE) is expected to report its Q4 earnings on Thursday before the market opens, with analysts projecting a 5% year-on-year revenue decline to $331.1 million and adjusted earnings of $1.25 per share. Despite a strong previous quarter where they beat revenue expectations, the stock has recently underperformed its peers in the healthcare equipment and supplies segment, being down 21% over the last month. Analysts have generally reconfirmed their estimates, suggesting they anticipate the company to stay on course.
A Glimpse Into The Expert Outlook On Haemonetics Through 11 Analysts
Eleven analysts have provided ratings for Haemonetics (NYSE: HAE) over the last three months, showing a mixed but generally positive sentiment. The average 12-month price target for HAE has increased by 7.78% to $88.09, with a high estimate of $99.00 and a low of $74.00. The article also details Haemonetics' financial performance, highlighting its impressive net margin, return on equity, and return on assets, despite a negative revenue trend in the last quarter.
Haemonetics (NYSE:HAE) Receives Outperform Rating from Barrington Research
Barrington Research has reaffirmed an "Outperform" rating for Haemonetics (NYSE:HAE), setting a $93.00 price target, which suggests a potential upside of approximately 39.8%. This comes after Haemonetics exceeded its last quarter's earnings estimates and provided a strong FY2026 EPS guidance. The stock currently holds a consensus "Moderate Buy" rating from analysts with an average target price of $84.40.
Earnings Beat And Vivasure Deal Might Change The Case For Investing In Haemonetics (HAE)
Haemonetics (HAE) recently exceeded Q3 revenue expectations and completed its acquisition of Vivasure Medical, signaling a push to expand its blood and vascular management portfolio. While these developments reinforce management’s strategy to broaden into vascular closure and implantable technologies, opening new growth catalysts, investors should consider integration risks and the company's relatively high debt. The stock's strong post-earnings movement suggests some enthusiasm is already priced in, and fair value estimates vary significantly among investors.
Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition
Haemonetics (HAE) has garnered confidence from analysts following its acquisition of Vivasure Medical. Michael Petusky from Barrington reiterated an Outperform rating and raised his price target to $93, while Anthony Petrone from Mizuho Securities also maintained an Outperform rating with a raised price target of $90. Both analysts view the Vivasure acquisition and the company's position in the medical devices sector favorably.
Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition
Haemonetics (HAE) has garnered confidence from analysts following its acquisition of Vivasure Medical. Michael Petusky of Barrington maintained an Outperform rating and raised the price target to $93, citing optimism for the deal. Anthony Petrone of Mizuho Securities also reaffirmed his Outperform rating, increasing the price target to $90 and suggesting further valuation expansion for the medical device company.
Autotransfusion Devices Market to See Thriving Worldwide | Haemonetics Corporation • Fresenius Kabi AG • Terumo Corporation
The "Autotransfusion Devices Market" report by Coherent Market Insights projects significant growth from 2025 to 2032, driven by increasing demand and innovation. It provides a comprehensive analysis of market trends, key players like Haemonetics Corporation and Medtronic plc, regional landscapes, and growth opportunities. The report aims to equip businesses with validated data and strategic insights for informed decision-making in this expanding global market.
Y Intercept Hong Kong Ltd Invests $2.28 Million in Haemonetics Corporation $HAE
Y Intercept Hong Kong Ltd recently invested $2.28 million in Haemonetics Corporation, acquiring a 0.10% stake. This investment comes as Haemonetics reports strong quarterly earnings, beating estimates with a revenue of $327.3 million and setting an optimistic FY2026 EPS guidance. Wall Street analysts maintain a "Moderate Buy" consensus for the stock with an average target price of $84.40.
Reflecting On Medical Devices & Supplies - Specialty Stocks' Q3 Earnings: Haemonetics (NYSE:HAE)
This article analyzes the Q3 earnings of specialty medical devices and supplies stocks, highlighting Haemonetics (NYSE:HAE) as a top performer with strong revenue beats despite a year-on-year decrease. It also reviews the performance of other companies in the sector, including STAAR Surgical (NASDAQ:STAA), Integer Holdings (NYSE:ITGR), Bausch + Lomb (NYSE:BLCO), and Enovis (NYSE:ENOV), detailing their revenue, analyst beats, and stock price movements. The broader industry faces demographic tailwinds and innovation opportunities but also challenges from regulatory hurdles and pricing pressures.
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Brokerages have given Haemonetics Corporation (NYSE:HAE) a consensus "Moderate Buy" rating with an average one-year price target of $84.40. The company recently surpassed quarterly EPS expectations and provided optimistic FY2026 guidance, despite a slight year-over-year revenue decrease. Institutional investors have also shown increased interest in the medical instruments supplier.
Autotransfusion System Market is expected to reach US$ 1,094.30 million by 2033 | Major players - Medtronic, LivaNova PLC, Haemonetics Corporation, Hemoclear.
The global Autotransfusion System Market, valued at US$ 575.29 million in 2024, is projected to reach US$ 1,094.30 million by 2033, demonstrating a CAGR of 7.4% from 2025 to 2033. This growth is driven by the increasing adoption of these medical devices which collect and reinfuse a patient's own blood, reducing reliance on donor blood and minimizing associated risks. Key players in this market include Medtronic, LivaNova PLC, and Haemonetics Corporation, with significant recent developments in the US and Japan focusing on portable units, AI integration, and expanded FDA/PMDA approvals.
Schwartz Investment Counsel Inc. Has $6.69 Million Stock Holdings in Haemonetics Corporation $HAE
Schwartz Investment Counsel Inc. significantly reduced its stake in Haemonetics Corporation ($HAE) by 63.2% in the third quarter, now holding 137,250 shares valued at $6.69 million. Despite this, Haemonetics reported strong Q3 results, exceeding analyst estimates for EPS and revenue, and issued positive FY2026 guidance. Institutional investors collectively own 99.67% of the company, with several firms increasing their positions.
Mizuho Markets Americas LLC Has $6.45 Million Stake in Haemonetics Corporation $HAE
Mizuho Markets Americas LLC significantly reduced its holdings in Haemonetics Corporation by 43.9% in Q3, ending with a stake valued at $6.45 million. Despite this, Haemonetics reported strong Q3 earnings, surpassing analyst expectations, and provided positive FY2026 guidance. Wall Street maintains a "Moderate Buy" consensus for the stock, with several firms, including Mizuho, raising price targets.
Haemonetics price target raised to $93 from $90 at Barrington
Barrington has increased its price target for Haemonetics (HAE) to $93 from $90, while maintaining an Outperform rating. This adjustment follows Haemonetics' acquisition of Vivasure Medical Limited, a developer of advanced polymer implants and delivery systems. The firm believes the Vivasure transaction positively impacts Haemonetics' prospects, leading to the revised price target.
Haemonetics Corp (HAE) Trading Down 3.8% on Jan 13
Haemonetics Corp (HAE) saw its shares fall by 3.80% in mid-day trading on January 13, settling at $79.77. Despite the decline, analysts forecast an average target price of $92.00, suggesting a 15.33% upside, with an "Outperform" recommendation. GuruFocus estimates an even higher fair value of $97.12 for HAE, implying a 21.75% upside.
New Hope’s Orchestra BioMed Set to Receive $21M from Vivasure Sale
New Hope's Orchestra BioMed Holdings is expected to receive up to $21 million from the acquisition of Ireland-based Vivasure by Haemonetics Corporation. Orchestra BioMed, a Bucks County biomedical innovation company, held a strategic stake in Vivasure. The proceeds will be delivered through upfront cash payments, milestone payments, and future revenue earnouts.
Galway’s Vivasure Medical acquired by Haemonetics in €185m deal
Galway-based medtech company Vivasure Medical has been acquired by US medical device company Haemonetics Corporation in a deal valued at up to €185m. Vivasure Medical, known for its PerQseal and PerQseal Elite technologies that seal blood vessels without leaving material behind, will leverage Haemonetics' global scale to accelerate the availability of its products. Haemonetics had previously made a strategic investment in Vivasure Medical in 2022 and provided €30m in funding in 2023.
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Holdings, Inc. announced it expects to receive up to $21 million in cash proceeds from the acquisition of Vivasure Medical Limited by Haemonetics Corporation. Vivasure was a strategic holding of Orchestra BioMed and its PerQseal® Elite system offers a unique vessel closure technology. Orchestra BioMed plans to receive $11 million in 2026, with the remainder in future revenue earnouts based on milestone achievements.
Ireland: Haemonetics Corporation acquires Vivasure Medical for up to €185m
Haemonetics Corporation, a US-listed medtech company, has acquired Ireland-based Vivasure Medical for up to €185 million (€100 million upfront cash, with up to €85 million contingent on sales growth and milestones). Vivasure Medical specializes in advanced polymer implants for minimally invasive vessel closure. This acquisition expands Haemonetics' portfolio in the large-bore closure market and strengthens its presence in structural heart and endovascular procedures.
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Orchestra BioMed is set to receive up to $21 million in cash from the acquisition of Vivasure Medical by Haemonetics Corporation, a deal that closed on January 9, 2026. Orchestra BioMed, having been a strategic holding of Vivasure, expects to receive $11 million in 2026, with the remaining proceeds tied to future revenue earnouts and milestones. The transaction highlights the success of Vivasure's PerQseal Elite system for percutaneous vessel closure.
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Holdings, Inc. announced that it expects to receive up to $21 million in cash proceeds from the acquisition of Vivasure Medical Limited by Haemonetics Corporation. Orchestra BioMed, having been a strategic holding of Vivasure, anticipates an initial $11 million in 2026, with the remainder from future revenue earnouts. Vivasure's PerQseal® Elite system, a percutaneous vessel closure technology, has demonstrated strong clinical results and regulatory approvals in Europe.
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
EQT Life Sciences has announced the sale of its portfolio company Vivasure Medical to Haemonetics Corporation. Vivasure Medical, known for its PerQseal® Elite system which provides a sutureless vessel closure solution, will be acquired for an upfront cash payment of EUR 100 million and up to an additional EUR 85 million in contingent consideration. This acquisition aims to expand Haemonetics' presence in the large-bore closure market and enhance its offerings in structural heart and endovascular procedures.
